HK Stock MarketDetailed Quotes


  • 40.550
  • -0.200-0.49%
Market Closed Jul 19 16:08 CST
66.03BMarket Cap-58177P/E (TTM)

About INNOVENT BIO Company

Established in 2011, Cinda Biopharmaceutical Group is a leading biopharmaceutical company with the mission of developing high-quality biopharmaceuticals that ordinary people can use. The company develops, produces and sells innovative drugs for major diseases such as oncology, cardiovascular and metabolic, autoimmune and ophthalmology. The company has reached more than 30 strategic partnerships with international partners such as Eli Lilly, Sanofi, Incyte, Adimab, LG Chem, and MDanderson Cancer Center. “Beginning with Trust, Achieving Action”, the company adheres to the highest standards of industry standards and hopes to work with industry colleagues to promote the development of the biopharmaceutical industry to meet the broad demand for first-class pharmaceuticals. Product pipeline summary Thanks to the company's multi-functional integrated platform and strategic partnerships, the company has established a strong research pipeline with 36 kinds of high-value products. The company has been approved for marketing of 10 products, namely Cindilizumab Injection (Daberzumab), Bevacizumab Injection (Dayu), Adalimumab Injection (Sulisin), Rituximab Injection (Daboxib), Pemitinib (Dabbotan), Olebatinib (Nellik), Remocizumab Injection (Shiranze), Ceptinib Capsules (Rituil), Iquiolenxil Injection (Fucosil), and Iquiolenxil Injection (Fucosil), and Iquiolenxil Injection (Fucosil) Monoclonal Antibody Injection (Cempira). In addition, there are 3 varieties in the NMPA review, 5 new drug molecules have entered phase III or key clinical research, and 18 new drug types have entered clinical research.

Company Profile

Listing DateOct 31, 2018
Issue Price13.98
Shares Offered236.35M share(s)
FoundedApr 28, 2011
Registered AddressCayman Islands
Chairmandechao yu
Secretaryyanjuchenluoer wang
Audit InstitutionDeloitte & Touche Tohmatsu Certified Public Accountants
Company CategoryOverseas registration of Mainland Individuals control
Registered OfficeMaples Corporate Services Limited PO Box 309, Ugland House, Grand Cayman KY1-1104 Cayman Islands
Head Office and Principal Place of BusinessRoom 1901, 19th floor, Lee Garden Phase I, 33 Hysan Avenue, Causeway Bay, Hong Kong
Fiscal Year Ends12-31
MarketHong Kong motherboard
Business Cinda Biopharmaceuticals is an investment holding company mainly engaged in biopharmaceuticals. The company and its subsidiaries are engaged in the research and development of antibody and protein pharmaceutical products, the sale and distribution of pharmaceuticals, and the provision of consulting and R&D services. The company's main product is dabercib (cindilizumab injection), which is used to treat recurrent or refractory classic Hodgkin lymphoma. The company's products also include the adalimumab antibiotic analogue IBI-303, which is used to treat rheumatoid arthritis, ankylosing spondylitis, and psoriasis. IBI-305, an antibiotic similar to bevacizumab, is used to treat metastatic colorectal cancer and advanced, metastatic, or recurrent non-small cell lung cancer (NSCLC). IBI-301, an antibiotic similar to rituximab, is used to treat non-Hodgkin lymphoma and chronic lymphocytic leukemia. The company's products are used in the fields of oncology, metabolism, immunology and fundus diseases.

Company Executives

  • Name
  • Position
  • Salary
  • dechao yu
  • presidencies,CEOs,President,Executive Director,Chairman of the Strategy Committee,Chairman of the Nomination Committee,Remuneration Committee Members
  • --
  • hao xi
  • Executive Director,Strategy Committee Members,Authorized Representative
  • --
  • qian zhang
  • Executive Director,Strategy Committee Members
  • --
  • Charles Leland Cooney
  • Independent Non-Executive Director,Audit Committee Members,Nomination Committee Members,Strategy Committee Members
  • --
  • yiyin xu
  • Independent Non-Executive Director,Chairman of the Audit Committee,Remuneration Committee Chairman
  • --
  • kaixian chen
  • Independent Non-Executive Director,Audit Committee Members,Remuneration Committee Members,Nomination Committee Members
  • --
  • Gary Zieziula
  • Independent Non-Executive Director,Audit Committee Members,Strategy Committee Members
  • --
  • shuyun chen
  • Independent Non-Executive Director,Remuneration Committee Members,Nomination Committee Members,Strategy Committee Members
  • --
  • shun lu
  • Independent Non-Executive Director,Strategy Committee Members
  • --
  • fei you
  • chief financial officer
  • --
  • yanju wang
  • Joint Company Secretary
  • --
  • luoer chen
  • Joint Company Secretary,Authorized Representative
  • --


Analyst Rating

No Data

Price Target

No Data

Heat List
Latest Price